Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease

YuanYuan Gu, Isaac T. W. Harley, Lindsay B. Henderson, Bruce J. Aronow, Ilja Vietor, Lukas A. Huber, John B. Harley, Jeffrey R. Kilpatrick, Carl D. Langefeld, Adrienne H. Williams, Anil G. Jegga, Jing Chen, Marsha Wills-Karp, S. Hasan Arshad, Susan L. Ewart, Chloe L. Thio, Leah M. Flick, Marie-Dominique Filippi, H. Leighton Grimes, Mitchell L. Drumm, Garry R. Cutting, Michael R. Knowles and Christopher L. Karp ()
Additional contact information
YuanYuan Gu: Division of Molecular Immunology,
Isaac T. W. Harley: Division of Molecular Immunology,
Lindsay B. Henderson: McKusick-Nathans Institute of Genetic Medicine, and,
Bruce J. Aronow: Division of Biomedical Informatics,
Ilja Vietor: Biocenter, Innsbruck Medical University
Lukas A. Huber: Biocenter, Innsbruck Medical University
John B. Harley: Arthritis & Immunology Program, Oklahoma Medical Research Foundation, and JK Autoimmunity Inc., Oklahoma City, Oklahoma 73104, USA
Jeffrey R. Kilpatrick: Arthritis & Immunology Program, Oklahoma Medical Research Foundation, and JK Autoimmunity Inc., Oklahoma City, Oklahoma 73104, USA
Carl D. Langefeld: Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA
Adrienne H. Williams: Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA
Anil G. Jegga: Division of Biomedical Informatics,
Jing Chen: Division of Biomedical Informatics,
Marsha Wills-Karp: and
S. Hasan Arshad: The David Hide Asthma and Allergy Research Centre, Newport, Isle of Wight, PO30 5TG, UK
Susan L. Ewart: College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA
Chloe L. Thio: Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Leah M. Flick: Division of Molecular Immunology,
Marie-Dominique Filippi: Cincinnati Children’s Hospital Research Foundation and the University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
H. Leighton Grimes: and
Mitchell L. Drumm: Case Western Reserve University, Cleveland, Ohio 44106, USA
Garry R. Cutting: McKusick-Nathans Institute of Genetic Medicine, and,
Michael R. Knowles: Cystic Fibrosis–Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Christopher L. Karp: Division of Molecular Immunology,

Nature, 2009, vol. 458, issue 7241, 1039-1042

Abstract: Cystic fibrosis: susceptibility to lung disease The severity of lung disease in patients with cystic fibrosis varies markedly between individuals, and has been shown to have considerable heritability, independent of the genotype of the CFTR (cystic fibrosis transmembrane regulator) mutation that causes the primary disease. Genomic analysis of more than 300 cystic fibrosis patients has led to the identification of the neutrophil transcriptional co-regulator IFRD1 as a genetic modifier for lung disease, acting via an effect on neutrophil effectors. This finding highlights IFRD1 as a possible drug target in cystic fibrosis, of potential clinical significance because lung disease is the major cause of morbidity and mortality in the condition.

Date: 2009
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature07811 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:458:y:2009:i:7241:d:10.1038_nature07811

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07811

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().